| |
|
|
|
|
|
|
|||
|
Blood, 15 December 2006, Vol. 108, No. 13, pp. 4146-4155. Prepublished online as a Blood First Edition Paper on August 22, 2006; DOI 10.1182/blood-2006-06-026716.
NEOPLASIA Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classificationFrom the Institute of Hematology, University of Perugia, Italy; the Institute for Cancer Genetics and the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY; the Institute of Hematology, University of Foggia, Italy; the Institute of Hematology, University of Bari, Italy; the Institute of Internal Medicine, University of Perugia, Italy; the Institute of Hematology, University "La Sapienza," Rome, Italy; the Hematology Service, "Moscati" Hospital, Avellino, Italy; the Institute of Hematology, "Ferrarotto" Hospital, Catania, Italy; and the Institute of Hematology, Policlinico S. Orsola, Bologna, Italy.
Because of a lack of specific clonality markers, information on lineage involvement and cell of origin of acute myeloid leukemia with normal karyotype (AML-NK), is missing. Because Nucleophosmin (NPM) gene is frequently mutated in AML-NK and causes aberrant NPM cytoplasmic localization (NPMc+), it was used as an AML lineage clonality marker. Clonal NPM exon 12 mutations were detected in myeloid, monocytic, erythroid, and megakaryocytic cells but not in fibroblasts or endothelia that were laser-microdissected from 3 patients with NPMc+ AML. Aberrant cytoplasmic expression of mutated NPM proteins was identified with anti-NPM antibodies in 2 or more myeloid hemopoietic cell lineages in 99 (61.5%) of 161 of NPMc+ AML paraffin-embedded bone marrow biopsies; lymphoid involvement was excluded in 3 investigated cases. These findings suggest that NPMc+ AML derives from either a common myeloid or earlier progenitor. Immunohistochemical studies show that varying combinations and ratios of NPMc+ leukemic cells from distinct lineages are responsible for heterogeneity within each French-American-British (FAB) classification type and for NPMc+ AML falling into different FAB categories. These findings question the value of FAB criteria in subdividing the WHO category of "AML not otherwise characterized" and suggest that, for clinical use, NPMc+ AML be provisionally regarded as a separate AML with prognostic significance.
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||